Case series of 21 patients with Acute Respiratory Failure in Critical COVID-19 and multiple co-morbidities, treated with intravenous Vasoactive Intestinal Peptide
Latest Information Update: 21 Oct 2021
Price :
$35 *
At a glance
- Drugs Aviptadil (Primary)
- Indications COVID 2019 infections; Respiratory insufficiency
- Focus Therapeutic Use
- 14 Oct 2021 According to NRx Pharmaceuticals media release, results from this study published at Journal of Infectious Diseases and Treatment.
- 14 Oct 2021 Results published in the NRx Pharmaceuticals Media Release
- 27 Jun 2021 New trial record